{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:32:04Z","timestamp":1791351124245,"version":"4.3.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":4885,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1093\/annonc\/mdl119","type":"journal-article","created":{"date-parts":[[2006,6,10]],"date-time":"2006-06-10T00:39:26Z","timestamp":1149899966000},"page":"1249-1254","source":"Crossref","is-referenced-by-count":20,"title":["First-line 5-fluorouracil\/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer"],"prefix":"10.1016","volume":"17","author":[{"given":"G.","family":"Masi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Loupakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Barbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Allegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Murr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cupini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Andreuccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdl119_bb0010","first-page":"198","article-title":"In: Steward BW, Kleihues P (eds)","author":"Cancer","year":"2003","journal-title":"World Cancer Report. Lyon: IACR Press"},{"key":"10.1093\/annonc\/mdl119_bb0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdl119_bb0020","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1093\/annonc\/mdl119_bb0025","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1200\/JCO.2005.05.546","article-title":"Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986","volume":"23","author":"Kohne","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl119_bb0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"181","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl119_bb0035","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"De Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl119_bb0040","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdl119_bb0045","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"issue":"11","key":"10.1093\/annonc\/mdl119_bb0050","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial","volume":"21","author":"Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl119_bb0055","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.3506","article-title":"N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin\/5-fluorouracil (5FU)\/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU","author":"Pitot","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl119_bb0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl119_bb0065","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl119_bb0070","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl119_bb0075","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2002.12.075","article-title":"Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer","volume":"20","author":"Falcone","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdl119_bb0080","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdh470","article-title":"First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil\/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule","volume":"15","author":"Masi","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdl119_bb0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1245\/ASO.2006.03.094","article-title":"Treatment with 5-fluorouracil\/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer","volume":"13","author":"Masi","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdl119_bb0090","article-title":"I Biweekly irinotecan, oxaliplatin and infusional 5FU\/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)","author":"Falcone","year":"2006","journal-title":"Proceedings ASCO Gastro-Intestinal Symposium"},{"issue":"4","key":"10.1093\/annonc\/mdl119_bb0095","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1093\/annonc\/mdl119_bb0100","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl119_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.2","article-title":"High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200","author":"Giantonio","year":"2005","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419476199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419476199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/8\/1249\/417595\/mdl119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T16:53:53Z","timestamp":1582217633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419476199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0923753419476199"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl119","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}